<DOC>
	<DOCNO>NCT00641056</DOCNO>
	<brief_summary>The purpose study compare effect 2.0 mg exenatide weekly insulin glargine , titrate glucose target use algorithm describe Yki- Järvinen et al . ( 2007 ) , respect glycemic improvement , body weight , fast lipid , safety , tolerability .</brief_summary>
	<brief_title>Efficacy Exenatide Once Weekly Once-Daily Insulin Glargine Patients With Type 2 Diabetes Treated With Metformin Alone Combination With Sulfonylurea ( DURATION - 3 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Has type 2 diabetes least 18 year age screening . Hemoglobin A1c ( HbA1c ) 7.1 % 11.0 % , inclusive , screen . Body mass index ( BMI ) 25 kg/m2 45 kg/m2 , inclusive , screen . Have history stable body weight ( vary &gt; 5 % least 3 month prior screen ) . Have treat metformin ( Met ) least 3 month take stable dose least 8 week prior screen OR Have treat metformin ( Met ) least 3 month take stable dose least 8 week prior screen treat SU least 3 month take stable dose least optimally effective dose brand SU 8 week prior screen . Have clinically significant history cardiac disease presence active cardiac disease within year prior inclusion study , include myocardial infarction , clinically significant arrhythmia , unstable angina , moderate severe congestive heart failure , coronary artery bypass surgery , angioplasty ; expect require coronary artery bypass surgery angioplasty course study . Have clinical sign symptom liver disease , acute chronic hepatitis . Have history renal transplantation currently receive renal dialysis . Have active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) less 5 year . Have great three episode major hypoglycemia within 6 month prior screen . Have contraindication oral antidiabetic agent use . Have know allergy hypersensitivity insulin glargine , exenatide weekly , excipients contain agent . Are know active proliferative retinopathy . Have treat drug promote weight loss ( e.g. , Xenical® [ orlistat ] , Meridia® [ sibutramine ] , Acomplia® [ rimonabant ] , Acutrim® [ phenylpropanolamine ] , similar overthecounter medication ) within 3 month screen . Have treat longer 2 week follow excluded medication within 3 month prior screen : Insulin Thiazolidinediones ( e.g. , Actos® [ pioglitazone ] Avandia® [ rosiglitazone ] ) Alphaglucosidase inhibitor ( e.g. , Glyset® [ miglitol ] Precose® [ acarbose ] ) Meglitinides ( e.g. , Prandin® [ repaglinide ] Starlix® [ nateglinide ] ) . Byetta® ( exenatide BID formulation ) Dipeptidyl peptidase ( DPP ) 4 inhibitor ( e.g. , Januvia™ [ sitagliptin ] , Galvus® [ vildagliptin ] ) Symlin® ( pramlintide acetate ) . Have organ transplant . Have donate blood within 30 day screen . Have previously complete withdrawn study study investigate exenatide weekly . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Are currently enrol clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>exenatide weekly</keyword>
	<keyword>metformin</keyword>
	<keyword>sulfonylurea</keyword>
	<keyword>insulin glargine</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>